6 completed, 3 active not recruiting, 2 recruiting, 1 not yet recruiting. 12 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 6, Active not recruiting 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Imlunestrant: new trials by email Literature Review of Imlunestrant trials Research Report on Imlunestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer PRT13722, Fulvestrant, Abemaciclib - Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 242 | 2026-11-16 | 2026-11-12 |
| A Study of Imlunestrant (LY3484356) in Healthy Female Participants Imlunestrant (Test), Imlunestrant (Reference), Omeprazole - Healthy | Phase 1 | Not yet recruiting | Eli Lilly and Company | 343 | 2026-11-01 | 2026-11-05 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 880 | 2023-04-17 | 2026-07-07 |
| A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer LY3484356 - Breast Neoplasms | Phase 1 | Active not recruiting | Eli Lilly and Company | 17 | 2022-10-09 | 2026-04-13 |
| A Study of Imlunestrant (LY3484356) in Healthy Women Midazolam, Imlunestrant - Healthy | Phase 1 | Completed | Eli Lilly and Company | 20 | 2022-09-12 | 2025-11-12 |
| A Study of Imlunestrant (LY3484356) in Female Healthy Participants Imlunestrant, Repaglinide, Omeprazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 113 | 2022-07-07 | 2025-12-12 |
| A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function Imlunestrant - Hepatic Insufficiency, Healthy | Phase 1 | Completed | Eli Lilly and Company | 27 | 2022-07-05 | 2025-11-12 |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors LOXO-783, Fulvestrant, Imlunestrant - Breast Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 260 | 2022-05-11 | 2026-10-14 |
| A Study of [¹⁴C]-LY3484356 in Healthy Female Participants [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV) - Healthy | Phase 1 | Completed | Eli Lilly and Company | 16 | 2021-08-13 | 2025-12-05 |
| A Study of LY3484356 in Healthy Female Participants LY3484356, Omeprazole, Itraconazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 82 | 2021-04-26 | 2025-12-11 |
| A Study of LY3484356 in Women With Breast Cancer Before Having Surgery LY3484356 - Breast Cancer | Phase 1 | Completed | Eli Lilly and Company | 87 | 2021-04-21 | 2025-11-12 |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer LY3484356, Abemaciclib, Everolimus - Breast Cancer, Advanced Breast Cancer | Phase 1 | Active not recruiting | Eli Lilly and Company | 379 | 2019-12-10 | 2026-06-22 |
Breast Neoplasms (6) · Endometrial Neoplasms (2) · Breast Diseases (1) · Head and Neck Neoplasms (1) · Hepatic Insufficiency (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Eli Lilly and Company (11) · Prelude Therapeutics Incorporated (1)
United States (11) · Belgium (4) · France (4) · Spain (4) · Germany (3) · Japan (3) · Australia (2) · China (2) · South Korea (2) · United Kingdom (2) · Canada (1) · Ireland (1) · Italy (1) · Netherlands (1) · Singapore (1)
2019 (1), 2023 (1)